Latest News and Press Releases

Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.

Lipid accumulation in the kidneys' filtration system results in inflammation and fibrosis that cause progressive kidney damage and disease progression.

KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening...

ZyVersa provides regulatory and product support for Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a patient with ApoCII amyloidosis.

Site initiation for Phase 2a DKD trial marks a key milestone for ZyVersa, and for development of VAR 200, a first-in-class treatment for kidney disease.

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...

Parasol group recommended reduction in proteinuria over 24 months as a surrogate endpoint for full approval of FSGS drugs.

ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones.

Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.

ZyVersa engages CRO, George Clinical, to manage its P2a clinical trial with VAR 200 in Diabetic Kidney Disease expected to begin Q1-2024.